Cross-reactivity assessment of carbamazepine-10,11-epoxide, oxcarbazepine, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassays: PETINIA and EMIT 2000

Therapeutic Drug Monitoring

Volumn 25, Issue 1, 2003, Pages 41-45

  Parant, François ^a   Bossu, Hubert ^a   Gagnieu, Marie Claude ^a   Lardet, Gisèle ^a   Moulsma, Mustapha ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Carbamazepine; Carbamazepine 10,11 epoxide; EMIT 2000; Oxcarbazepine; PETINIA

Indexed keywords

CARBAMAZEPINE 10,11 OXIDE; DRUG METABOLITE; LICARBAZEPINE; OXCARBAZEPINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SCREENING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOASSAY; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; QUALITY CONTROL;

ADULT; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS REACTIONS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; IMMUNOASSAY; LINEAR MODELS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY;

EID: 0037304433     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200302000-00006     Document Type: Article

References (13)

1. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacol 1986;11:177-98.
2. Potter JM, Donnelly A. Carbamazepine-10,11-epoxide in therapeutic drug monitoring. Ther Drug Monit 1998;20:652-7.
3. Ramsay RE, McManus DQ, Guterman A, et al. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. Ther Drug Monit 1990;12:235-41.
4. Liu H, Delgado MR. Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy. Ther Drug Monit 1994;16:132-8.
5. Robbins DK, Wedlund PJ, Kuhn WR, et al. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 1990;29:759-62.
6. Shen S, Elin RJ, Soldin SJ. Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays. Clin Biochem 2001;34:157-8.
7. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(suppl 3):S10-3.
8. Thompson JC, Craig AR, Davey CL, et al. Kinetics and proposed mechanism of the reaction of an immunoinhibition, particle-enhanced immunoassay. Clin Chem 1997;43:2384-9.
9. Rambeck B, May TW, Jürgens U, et al. Comparison of phenytoin and carbamazepine serum concentrations measured by highperformance liquid chromatography, the standard TDx assay, the enzyme multiplied immunoassay technique, and a new patient-side immunoassay cartridge system. Ther Drug Monit 1994;16:608-12.
10. Tomson T, Almkvist O, Nilsson BY, et al. Carbamazepine-10,11-epoxide in epilepsy. A pilot study. Arch Neurol 1990;47:888-92.
11. So EL, Ruggles KH, Cascino GD, et al. Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann Neurol 1994;35:743-6.
12. Tibbals J. Acute toxic reaction to carbamazepine: clinical effects and serum concentrations. J Pediatr 1992;121:295-9.
13. Deshpande G, Meert KL, Valentini RP. Repeat charcoal hemoperfusion treatments in life threatening carbamazepine overdose. Pediatr Nephrol 1999;13:775-7.